A phase I/II study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (PTS) with advanced or metastatic colorectal cancer (MCRC)

被引:0
|
作者
Maroun, Jean A. [1 ]
Jonker, Derek [1 ]
Goel, Rakesh [1 ]
Cripps, Christine [1 ]
Lister, Diane [1 ]
Chiritescu, Gabriela [1 ]
机构
[1] Ottawa Hosp, Reg Canc Ctr, Ottawa, ON, Canada
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
下载
收藏
页码:119 / 119
页数:1
相关论文
共 50 条
  • [1] Encouraging results from a phase I study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (pts) with metastatic colorectal cancer (MCRC)
    Maroun, J.
    Jonker, D.
    Cripps, C.
    Goel, R.
    Lister, D.
    Chiritescu, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Capecitabine (X), irinotecan (I) and bevacizumab (A) as first-line therapy for patients (PTS) with metastatic colorectal cancer (MCRC): Preliminary phase II study results
    Semir, Beslija
    Maja, Banjin
    Nadja, Paraganlija
    Timur, Ceric
    Anes, Pasic
    Berisa, Salkic
    Anes, Sosevic
    Nermina, Obralic
    ANNALS OF ONCOLOGY, 2006, 17 : 127 - 127
  • [3] Preliminary phase II study results of capecitabine (X) plus irinotecan (I) plus bevacizumab (A) as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Phase I/II study of capecitabine(C)/oxaliplatin(O)/ irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
    Ou, K.
    Liu, X.
    Ma, X.
    Gao, L.
    Wang, Q.
    Yang, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1514 - S1514
  • [5] A phase II trial of capecitabine (X) and irinotecan (I), in a biweekly schedule, for patients (Pts) with advanced/metastatic colorectal cancer (MCRC).
    Garcia-Alfonso, P
    Gonzalez-Arenas, C
    Gonzalez-Flores, E
    Molina, M
    Muñoz, A
    Abad, G
    Garcia-Adrian, S
    Lopez, P
    Belon, J
    Perez-Manga, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 290S - 290S
  • [6] Phase I study of the IXO regimen, irinotecan (I), capecitabine (X), oxaliplatin (O), as first-line therapy for metastatic colorectal cancer: Final survival results
    Maroun, J.
    Jonker, D.
    Cripps, C.
    Goel, R.
    Asmis, T.
    Marginean, H.
    Chiritescu, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Updated phase II study results of capecitabine (X) plus irinotecan (I) plus bevacizumab (A) as first-line therapy for metastatic colorectal cancer (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Smoljanovic, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] UPDATED PHASE II STUDY RESULTS OF CAPECITABINE (X) plus IRINOTECAN (I) plus BEVACIZUMAB (A) AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    ANNALS OF ONCOLOGY, 2008, 19 : 130 - 130
  • [9] UPDATED PHASE II STUDY RESULTS OF CAPECITABINE (X) plus IRINOTECAN (I) plus BEVACIZUMAB (A) AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Smoljanovic, V
    ANNALS OF ONCOLOGY, 2009, 20 : 76 - 76
  • [10] Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC)
    Salud, A.
    Escudero, P.
    Feliu, J.
    Lopez-Gomez, L.
    Bolanos, M.
    Galan, A.
    Yubero, A.
    Vicent, J. M.
    Losa, F.
    Gonzalez-Baron, M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 190 - 190